Content
Search
Navigation
Sitemap
About us
View this section
View this section
Who we are
Our model
Our investment process
Our NAV Growth Framework
Our purpose, culture and values
Our history
Our people
View this section
View this section
Board of Directors
Portfolio
View this section
View this section
Portfolio data
Late-stage clinical companies
Overview
Autolus Therapeutics
Beacon Therapeutics
Clinical companies
Overview
iOnctura
Spur Therapeutics
Quell Therapeutics
Pre-clinical companies
Overview
Resolution Therapeutics
Anaveon
Purespring Therapeutics
Forcefield Therapeutics
OMass Therapeutics
Mosaic Therapeutics
Kesmalea Therapeutics
Yellowstone Biosciences
Previous portfolio companies
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
Neogene Therapeutics
14MG
Azeria Therapeutics
Clade Therapeutics
Sustainability
View this section
View this section
Message from CEO, SIML
Our approach to sustainability reporting
Our social impact
Overview
Our patient impact framework
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Inspiring and empowering our people
Responsible and ethical business
Overview
Environment
Our first net zero target
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and insights
View this section
View this section
News
Insights & articles
Publications & presentations
Investors
View this section
View this section
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
Our Committees
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Events calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Portfolio data
Browse all portfolio data news
Search
Latest portfolio data news
Show news from
all companies
all companies
all Late-stage clinical companies companies
Autolus Therapeutics
Beacon Therapeutics
all Clinical companies companies
Spur Therapeutics
Quell Therapeutics
all Pre-clinical companies companies
Resolution Therapeutics
Anaveon
Clear filters
21.07.22
New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B
Operating News
10.07.22
Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress
10.06.22
Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Association Congress
11.04.22
Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022
Pre-clinical companies
Anaveon
08.02.22
Freeline Presents on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposiumTM
13.12.21
Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition
Late-stage clinical companies
Autolus Therapeutics
Load more
Close menu
About us
View this section
View this section
Who we are
Our model
Our investment process
Our NAV Growth Framework
Our purpose, culture and values
Our history
Our people
View this section
View this section
Board of Directors
Portfolio
View this section
View this section
Portfolio data
Late-stage clinical companies
Overview
Autolus Therapeutics
Beacon Therapeutics
Clinical companies
Overview
iOnctura
Spur Therapeutics
Quell Therapeutics
Pre-clinical companies
Overview
Resolution Therapeutics
Anaveon
Purespring Therapeutics
Forcefield Therapeutics
OMass Therapeutics
Mosaic Therapeutics
Kesmalea Therapeutics
Yellowstone Biosciences
Previous portfolio companies
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
Neogene Therapeutics
14MG
Azeria Therapeutics
Clade Therapeutics
Sustainability
View this section
View this section
Message from CEO, SIML
Our approach to sustainability reporting
Our social impact
Overview
Our patient impact framework
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Inspiring and empowering our people
Responsible and ethical business
Overview
Environment
Our first net zero target
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and insights
View this section
View this section
News
Insights & articles
Publications & presentations
Investors
View this section
View this section
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
Our Committees
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Events calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Search
Search